Thrombocytopenia Associated With Chronic Liver Disease Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Disease and Thrombocytopenia
| Verified date | December 2017 |
| Source | Eisai Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease. This study will assess the effect of avatrombopag on platelet counts in Japanese subjects. Subjects will be enrolled into 2 cohorts according to the mean platelet count measured at Screening and Baseline. Within the lower baseline platelet count cohort (less than 40 x 10^9/L), subjects will be randomized in a 1:1:1:3 ratio to receive placebo, 20 mg avatrombopag, 40 mg avatrombopag, or 60 mg avatrombopag for 5 days. Within the higher baseline platelet count cohort (from 40 to less than 50 x 10^9/L), subjects will be randomized in a 2:1:2 ratio to receive placebo, 20 mg avatrombopag, or 40 mg avatrombopag for 5 days.
| Status | Completed |
| Enrollment | 39 |
| Est. completion date | April 1, 2015 |
| Est. primary completion date | April 1, 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria 1. Japanese subjects greater than or equal to 20 years of age at Screening with chronic liver disease. 2. Subjects who have a mean baseline platelet count of less than 50 x 10^9/L. Platelet counts will be measured on 2 separate occasions, during the Screening Period and at Baseline, and must be performed at least one day apart with neither platelet count greater than 60 x 10^9/L. 3. Model For End-stage Liver Disease (MELD) score 24 at Screening. 4. If taking inhibitors of P glycoprotein (P-gp), except for verapamil, dose must be stable for 7 days prior to Screening. 5. Provide written informed consent. 6. Willing and able to comply with all aspects of the protocol. Exclusion Criteria 1. Any history of arterial or venous thrombosis, including partial or complete thrombosis. 2. Evidence of thrombosis (partial or complete) in the main portal vein, portal vein branches, or any part of the splenic mesenteric system at Screening. 3. Portal vein blood flow velocity rate less than 10 cm/second at Screening. 4. Hepatic encephalopathy that cannot be effectively treated. 5. Subjects with HCC with Barcelona Clinic Liver Cancer (BCLC) staging classification C or D. 6. Platelet transfusion or receipt of blood products containing platelets within 7 days of Screening. However packed red blood cells are permitted. 7. Heparin, warfarin, nonsteroidal anti-inflammatory drugs (NSAID), aspirin, verapamil, and antiplatelet therapy with ticlopidine or glycoprotein IIb/IIIa antagonists (eg, tirofiban) within 7 days of Screening. 8. Use of erythropoietin stimulating agents within 7 days of Screening. 9. Interferon (IFN) use within 14 days of Screening. 10. Estrogen-containing hormonal contraceptive or hormone replacement therapy use within 30 days of Screening. 11. Active infection requiring systemic antibiotic therapy within 7 days of Screening. However, prophylactic use of antibiotics is permitted. 12. Alcohol abuse, alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program) or acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start. 13. Known to be human immunodeficiency virus positive. 14. Any clinically significant acute or active bleeding (eg, gastrointestinal, central nervous system). 15. Known history of any primary hematologic disorder (eg, immune thrombocytopenic purpura, myelodysplastic syndrome). 16. Known medical history of genetic prothrombotic syndromes (eg, Factor V Leiden; prothrombin G20210A; ATIII deficiency etc.) 17. Subjects with a history of significant cardiovascular disease (eg, congestive heart failure New York Heart Association Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [eg, atrial fibrillation], coronary artery stent placement, angioplasty, and coronary artery bypass grafting). 18. Females of childbearing potential who have had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a progesterone only contraceptive implant/injection, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation. If currently abstinent, the subject must agree to use a double barrier method as described above if she becomes sexually active during the study period or for 30 days after study drug discontinuation. All females will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months consecutive amenorrhea in the appropriate age group and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 1 month before dosing. 19. Females who are lactating or pregnant at Screening or Baseline (as documented by a positive serum beta-human chorionic gonadotropin [B-hCG] test with a minimum sensitivity 25 IU/L or equivalent units of B-hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug. 20. Post liver transplant subjects. 21. Any subject who has previously received avatrombopag. 22. Hypersensitivity to avatrombopag maleate or any of its excipients. 23. Hemoglobin levels less than or equal to 8.0 or greater than or equal to 16.0 g/dL at Screening. 24. White blood cell count less than or equal to 1.5 x 10^9/L or greater than or equal to 15.0 x 10^9/L at Screening. 25. Serum sodium level less than or equal to 130 milliequivalents/L at Screening. 26. Current malignancy including solid tumors and hematologic malignancies (except HCC). 27. Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator(s), would compromise the subject's ability to safely complete the study. 28. Currently enrolled in another clinical trial or used any investigational drug or device within 30 days of Screening. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Eisai Co., Ltd. |
Japan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Safety assessments consisted of monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms; physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. A treatment-emergent adverse event (TEAE) was defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. For each category, a participant with two or more adverse events in that category was counted only once. Treatment-related TEAEs were considered by the investigator to be possibly or probably related to study drug or TEAEs with a missing causality. | From the date of first dose of study drug up to 30 days after the last dose of the study drug, up to approximately 10 months | |
| Other | Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Value (TEMAV) for Haematology | From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months) | ||
| Other | Number of Participants With Clinically Significant Findings in Laboratory Values for Serum | From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months) | ||
| Other | Number of Participants With Clinically Significant Findings in Laboratory Values for Urinalysis | From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months) | ||
| Other | Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values | From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months) | ||
| Other | Number of Participants With Markedly Abnormal Electrocardiographs | From the date of Screening until the date of last dose of study drug plus 30 days (Approximately 10 months) | ||
| Primary | Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L and at Least 20 x 10^9/L Increase From Baseline at Visit 4 | Responders were defined as participants whose platelet count was greater than or equal to 50×10^9/liter (L) and change from baseline was at least 20×10^9/L at Visit 4. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% confidence interval (CI) is calculated by Clopper and Pearson method. | Baseline and Visit 4 (Day 10) | |
| Secondary | Percentage of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Each Visit | Responders were defined as the participants whose platelet count greater than or equal to 50 x 10^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method. | Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35) | |
| Secondary | Percentage of Participants With Platelet Count Greater Than or Equal to 75 x 10^9/L at Each Visit | Responders were defined as the participants whose platelet count greater than or equal to 75 x 10^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. Two-sided 95% CI is calculated by Clopper and Pearson method. | Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35) | |
| Secondary | Percentage of Participants With Platelet Count Greater Than or Equal to 150 x 10^9/L At Each Visit | Responders were defined as the participants whose platelet count greater than or equal to 150 x 10^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. | Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35) | |
| Secondary | Percentage of Participants With Platelet Count Greater Than or Equal to 200 x 10^9/L At Each Visit | Responders were defined as the participants whose platelet count greater than or equal to 200 x 10^9/L by visit. Participants receiving a platelet transfusion prior to the platelet count assessment at Visit 4 were considered as non-responders in the analysis. | Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35) | |
| Secondary | Platelet Count and Change From Baseline in Platelet Count by Visit | Baseline, Visit 3 (Day 4 or 5), Visit 4 (Day 10), Visit 5 (Day 17) and Visit 6 (Day 35) |